Treatment and outcomes of symptomatic hyperammonemia following asparaginase therapy in children with acute lymphoblastic leukemia

Symptomatic hyperammonemia secondary to recombinant Erwinia asparaginase

(2023) Catherine E. Martin et al.   PEDIATRIC BLOOD & CANCER

Recombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia: Results from the Phase 2/3 AALL1931 Study

(2022) Luke D. Maese et al.   BLOOD

Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001

(2021) Lynda M. Vrooman et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children’s Oncology Group

(2020) Sumit Gupta et al.   JOURNAL OF CLINICAL ONCOLOGY

Late-Onset Ornithine Transcarbamylase Deficiency and Variable Phenotypes in Vietnamese Females With OTC Mutations

(2020) Huy-Hoang Nguyen et al.   Frontiers in Pediatrics

Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion

(2020) André Baruchel et al.   ESMO Open

Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision

(2019) Johannes Häberle et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Universal premedication and therapeutic drug monitoring for asparaginase‐based therapy prevents infusion‐associated acute adverse events and drug substitutions

(2019) Stacy L. Cooper et al.   PEDIATRIC BLOOD & CANCER

Hyperammonemia after capecitabine associated with occult impairment of the urea cycle

(2019) Gilbert Chu et al.   Cancer Medicine

Symptomatic Hyperammonemia With Erwinia chrysanthemi–derived Asparaginase in Pediatric Leukemia Patients

(2018) Nathan Gossai et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Pegylated asparaginase as cause of fatal hyperammonemia in patients with latent urea cycle disorder

(2018) Megan Peters et al.   PEDIATRIC BLOOD & CANCER

The complete European guidelines on phenylketonuria: diagnosis and treatment

(2017) A. M. J. van Wegberg et al.   Orphanet Journal of Rare Diseases

Efficacy and safety of i.v. sodium benzoate in urea cycle disorders: a multicentre retrospective study

(2016) Marie-Caroline Husson et al.   Orphanet Journal of Rare Diseases

The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia

(2014) W. H. Tong et al.   HAEMATOLOGICA

Pharmacokinetic and Pharmacodynamic Properties of Calaspargase PegolEscherichia coliL-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4

(2014) Anne L. Angiolillo et al.   JOURNAL OF CLINICAL ONCOLOGY

Hyperammonemia secondary to asparaginase: A case series

(2014) Vicki Nussbaum et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

l-asparaginase: an effective agent in the treatment of acute lymphoblastic leukemia

(2013) Kuldeep Kumar et al.   LEUKEMIA & LYMPHOMA

An unusual cause of hyperammonemia in a critically ill patient

(2012) Alexandre Brasseur et al.   INTENSIVE CARE MEDICINE

Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel

(2011) Wendy Stock et al.   LEUKEMIA & LYMPHOMA

Acute metabolic encephalopathy in two patients treated with asparaginase and ondasetron

(2010) Helene Sudour et al.   AMERICAN JOURNAL OF HEMATOLOGY

Transient Hyperammonemia Due to L -Asparaginase Therapy in Children with Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

(2010) C. Jörck et al.   PEDIATRIC HEMATOLOGY AND ONCOLOGY

Hyperammonemic Encephalopathy After Induction Chemotherapy for Acute Lymphoblastic Leukemia

(2009) Tang-Her Jaing et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY